LALPATHLAB · NSE
Dr. Lal Path Labs Ltd.
₹2,006
+2.18% (+₹42.8)
Prev. close
₹1,963.2
Volume
2,64,951
Delivery %
52.5%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Dr Lal Path Labs with a target price of ₹2,240, representing a 19% potential upside. The firm expects improve…” | Shriram Research AnalysisShriram Research | Dr Lal Path Labs | PENDING | |
| “Bullish on Dr. Lal Path Labs for the next one to two weeks, advising a buying range of ₹3,160–3,130 with a target of ₹3,…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Dr. Lal PathLabs Ltd. | MISS | |
| “Bullish on Dr. Lal Pathlabs Ltd, recommending a buy at ₹3,150 with a target of ₹3,225 and a stop loss at ₹3,110. The cal…” | Ankush BajajIndependent | Dr. Lal Pathlabs Ltd | MISS | |
| “Bullish on Dr. Lal PathLabs (LALPATHLAB), recommending a buy at current market price and on dips to ₹3,040, with a stop …” | Raja VenkatramanNeoTrader | Dr. Lal PathLabs | HIT | |
| “Emkay Global Financial recommends buying Dr. Lal PathLabs with a target price of ₹3,100.” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Dr. Lal PathLabs | PENDING | |
| “HDFC Securities maintains an 'add' rating on Dr Lal Pathlabs with a rolled-forward target price of ₹2,910, based on 43x …” | HDFC SecuritiesHDFC Securities | Dr Lal Pathlabs Ltd | PENDING | |
| “Bullish on Lal Path Lab, recommending a buy at ₹3419 with a target price of ₹3610 and a stop loss at ₹3327. The price ha…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Dr. Lal PathLabs Ltd. | PENDING |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on DR.LAL PATHLABS LTD, recommending a buy at the current price of ₹3,150. The stock is exhibiting strong bullis…” | Ankush BajajIndependent | Dr. Lal PathLabs Ltd | — |
Fundamentals
About Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Shankha Banerjee
Headquarters
Gurugram
Employees
5,206
Website
lalpathlabs.comExchange
View on NSE ↗Key stats
Market cap
₹33,933.74 Cr
P/E ratio (TTM)
62.7
Dividend yield
1.04%
EPS (TTM)
₹32.39
Beta (1Y · daily vs NIFTY 50)
0.38
Beta (5Y · monthly vs NIFTY 50)
0.89
Shares float
7.58 Cr
EPS · quarter ended Jun 2026
₹10.13
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,581.30 Cr | ₹2,087.40 Cr | ₹2,016.90 Cr | ₹2,226.60 Cr | ₹2,461.40 Cr | ₹2,762.90 Cr | |
EBITDA | ₹487.60 Cr | ₹613.20 Cr | ₹531.60 Cr | ₹678.50 Cr | ₹788.90 Cr | ₹853.70 Cr |
| ₹291.60 Cr | ₹344.80 Cr | ₹238.90 Cr | ₹357.70 Cr | ₹487.10 Cr | ₹504.80 Cr | |
Diluted EPS | ₹17.63 | ₹20.79 | ₹14.37 | ₹21.49 | ₹29.2 | ₹30.2 |
Net income for Mar 2021 could not be checked against the company's own annual report: this page shows ₹291.60 Cr while the annual report gives ₹296.50 Cr (1.7% apart). That disagreement leaves the whole cross-check inconclusive, so Net income for Mar 2020 (the annual report alone gives ₹227.60 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,661.00 Cr | ₹2,343.00 Cr | ₹2,383.00 Cr | ₹2,454.00 Cr | ₹2,713.00 Cr | ₹3,140.00 Cr | |
| — | ₹532.57 Cr | ₹419.50 Cr | ₹246.93 Cr | ₹157.43 Cr | ₹198.99 Cr | |
Stockholders' equity | ₹1,245.00 Cr | ₹1,501.00 Cr | ₹1,666.00 Cr | ₹1,849.00 Cr | ₹2,173.00 Cr | ₹2,509.00 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹398.00 Cr | ₹447.00 Cr | ₹456.00 Cr | ₹535.00 Cr | ₹569.00 Cr | ₹636.00 Cr | |
Investing cash flow | ₹-212.00 Cr | ₹-449.20 Cr | ₹-287.30 Cr | ₹-24.30 Cr | ₹-303.10 Cr | ₹-421.90 Cr |
| ₹-139.00 Cr | ₹136.00 Cr | ₹-283.00 Cr | ₹-414.00 Cr | ₹-334.00 Cr | ₹-264.00 Cr | |
Capital expenditure | ₹-60.00 Cr | ₹-476.00 Cr | ₹-45.00 Cr | ₹-57.00 Cr | ₹-54.00 Cr | ₹-173.00 Cr |
End cash position | ₹244.30 Cr | ₹378.20 Cr | ₹263.70 Cr | ₹360.90 Cr | ₹292.60 Cr | ₹242.80 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25–Dec 25(2Q) | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.23% | 55.23% | 55.23% | 55.05% | 55.05% | 55.05% | 55.03% | 55.01% | 54.61% | 54.60% | 54.60% | 54.60% | 53.92% | 53.91% | 53.91% | 53.79% | 53.21% | 53.21% | 53.21% | 53.19% |
| Public | 43.97% | 44.03% | 44.07% | 44.35% | 44.38% | 44.39% | 44.45% | 44.55% | 44.98% | 45.03% | 45.08% | 45.10% | 45.75% | 45.81% | 45.83% | 45.82% | 46.42% | 46.44% | 46.44% | 46.43% |
| Employee trusts | 0.80% | 0.74% | 0.70% | 0.60% | 0.58% | 0.56% | 0.51% | 0.44% | 0.41% | 0.37% | 0.32% | 0.30% | 0.33% | 0.28% | 0.27% | 0.39% | 0.37% | 0.35% | 0.34% | 0.38% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Dr. Lal Path Labs Ltd. | ₹32,199.77 Cr | ₹2,029.4 | 59.4 | 12.84 | 20.1% | 0.08 | +12.3% | -35.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Dr. Lal Path Labs Q2 profit soars 28% YoY, EBITDA margin expands; dividend of ₹5/share declared
Upstox · 18 days ago
Dr. Lal Path Labs (LALPATHLAB.NS) Eases 0.93% to ₹1934.2 as Diagnostics Major Holds Above Key Support - Max Pain Level
siam.in · 2 months ago